All posts by imreal

Technology: Electronics

Synapse Technology Engages Government Customers in Partnership with Federal Resources

Leave a comment


Syntech ONE is an AI-powered software platform that dramatically improves the effectiveness of checkpoint X-ray scanners by automating detection of prohibited items.


PALO ALTO, Calif. (PRWEB)

Artificial intelligence (AI) security and defense company Synapse Technology Corporation today announced it has expanded its sales and distribution reach across US federal customers via a partnership with distributor Federal Resources. Federal Resources will market, sell and support the company’s Syntech ONE platform for applications including aviation security, border security, and critical infrastructure protection.

Federal Resources is a solutions provider serving the Department of Defense, various Federal Agencies and first responders in various markets to include the Critical Infrastructure market. “Federal Resources is excited to be partnering with Synapse Technology to bring their revolutionary AI technology to new and existing Federal Government users to expand their training and X-ray interpretation capabilities for an expanding threat base. Syntech ONE will be one of Federal Resources’ flagship products within our Critical Infrastructure market. Adding this product to our portfolio will greatly enhance our ability to help the effectiveness of operator screening for threat detection. We’re thrilled to be able to demonstrate the Syntech ONE at our offices in Arlington, VA,” commented Matt Birnbaum, VP of Vertical Sales of Federal Resources.

Syntech ONE is an AI-powered software platform that dramatically improves the effectiveness of checkpoint X-ray scanners by automating detection of prohibited items. It retrofits onto both new and existing X-ray systems. Its growing threat detection library, which now includes ammunition in addition to gun components, sharps and knives, is the most extensive in the industry. Syntech ONE’s performance is superior to other commercially-available systems. Syntech ONE is deployed in live screening environments for aviation and critical infrastructure protection and has processed over 17,000,000 passenger bags. The US Department of Homeland Security (DHS) recognizes the value of Syntech ONE and has granted Synapse Technology Corporation a SAFETY Act award for its technology platform. In addition, the US Airforce recently awarded Synapse a contract, which allows US DOD and other US government customers to easily acquire the advanced software.

“Federal Resources is the perfect partner for Synapse. As we further build our federal customer relationships, Federal Resources puts us in the perfect position to deploy Synapse Technology throughout the United States government. In conjunction with our recent investment from In-Q-Tel, we are in a prime position to rapidly modernize security checkpoints with artificial intelligence.” commented Ian Cinnamon, President of Synapse Technology Corporation.

Synapse Technology recently entered into a strategic investment agreement with In-Q-Tel (IQT), the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to U.S. intelligence and defense agencies. “Synapse’s technology is disrupting the industry by using artificial intelligence to automatically identify threats at our country’s air, sea, and land ports of entry,” said A.J. Bertone, Partner, Investments, IQT.

About Synapse Technology

Synapse Technology’s AI platform Syntech ONE® integrates with new and existing X-ray machines used at security checkpoints. Instead of security screeners relying solely on human cognitive abilities to identify threats like guns and knives, Syntech ONE augments and automates the detection of these dangerous items. Syntech ONE has already been widely deployed, having processed over 17,000,000 passenger bags at security checkpoints in four countries. The US Department of Homeland Security (DHS) recognizes the value of Syntech ONE and has granted Synapse Technology Corporation a SAFETY Act award for its technology platform. For more information, visit synapsetechnology.com.

About Federal Resources

Founded in 1986, Federal Resources is a leading provider of quality products and mission-critical solutions that support the U.S. Military, Federal Government, State/Local Responders, and International Markets. Specializing in comprehensive life-cycle sustainment solutions; procurement and acquisition; technical services and asset management; and training expertise, the organization is dedicated to serving its diverse range of well-established and emerging market segments. Federal Resources strives to fulfill and expand upon its mission to ensure end-users are equipped with the most innovative, reliable, and cost-effective products and technologies available on the market.

For more information, please visit http://www.federalresources.com

About In-Q-Tel

In-Q-Tel (IQT) is the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to U.S. intelligence and defense agencies that keep our nation safe. IQT was established in 1999 with a distinct mission: to identify and partner with startup companies developing innovative technologies that protect and preserve our nation’s security. Visit http://www.iqt.org for more information.

Share article on social media or email:

Society: Disabled Issues / Disabilities

Worldwide Online Survey Aims to Identify a New Comprehensive Approach to Global Collaboration for Parkinson’s Disease

Leave a comment


https://www.prweb.com/

International Congress of Parkinson’s Disease and Movement Disorders®

It is becoming increasingly clear that even relatively common diseases like PD are highly etiologically heterogeneous syndromes and that progress towards early diagnosis and causative treatments will depend on the identification of sufficient numbers of well-defined subgroups.


NICE, France (PRWEB)

A worldwide online survey identifying genetic Parkinson’s disease (PD) patients demonstrates an overall need for global collaboration and new comprehensive approaches for PD, according to research released today at the International Congress of Parkinson’s Disease and Movement Disorders®.

The systematic online survey, developed by members of the Michael J. Fox Foundation Global Genetic Parkinson’s Study Group, collected demographic, clinical and genetic data from PD patients with specific genetic mutations. Using authors from articles represented in the MDSGene database as well as the GEoPD consortium, 336 researchers were identified worldwide to participate in the survey, of which 162 (48%) responded. Overall, 103 international sites in 43 countries reported 8,453 PD patients of more than 9 ethnicities with the genetic mutations. This is particularly significant given that the survey identified a three-fold higher number of patients with genetic PD when compared to the cases reported in the literature, indicating access to patients and data requires new approaches and means of communication.

Thomas Gasser, Director at the Department of Neurodegeneration at Hertie Institute for Clinical Brain Research, in Tuebingen, Germany, states “This initiative is of high relevance because it is becoming increasingly clear that even relatively common diseases like PD are highly etiologically heterogeneous syndromes and that progress towards early diagnosis and causative treatments will depend on the identification of sufficient numbers of well-defined subgroups. This will only be possible by collaborations at a very large, preferably worldwide scale.”

Gasser adds, “Of course, this survey is only a very first small step. If international team science is to become successful, many problems concerning standardization of patient ascertainment, data privacy and protection as well as data access and use need to be solved. Nevertheless, the survey raises awareness of these issues and it clearly shows that the PD research community is ready to begin to tackle these important issues.”

About the International Congress of Parkinson’s Disease and Movement Disorders®: Meeting attendees gather to learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson’s disease. Over 5,100 physicians and medical professionals from more than 95 countries will be in attendance to view 2, 200 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 8,500 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

health and fitness

Modere Inside-Out Beauty System Delivers 360°, Scientifically Advanced Approach to Natural Radiance

Leave a comment


https://www.prweb.com/

CellProof Essentials Collection

The Modere® Inside-Out Beauty System combines the company’s patented, award-winning collagen/HA nutraceutical Liquid BioCell® with the CellProof® Essentials Collection, a new trio of topical skincare essentials designed to augment the company’s recent viral hit, CellProof™ Serum.


LOS ANGELES (PRWEB)

On Saturday, September 21, Modere®, a healthy, safe and clean-lifestyle brand of dietary supplements, household and personal-care products with a presence worldwide, announced the North American launch of the Modere® Inside-Out Beauty System at their Fall Summit in Orlando, Florida. The Modere® Inside-Out Beauty System combines the company’s patented, award-winning collagen/HA nutraceutical Liquid BioCell® with the CellProof® Essentials Collection, a new trio of topical skincare essentials designed to augment the company’s recent viral hit, CellProof™ Serum.

The Modere ® CellProof™ Essentials Collection is comprised of CellProof™ Serum, CellProof™ Moisturizer, and CellProof™ Infusion Mask. CellProof™ Serum is an age-defying formula powered by BioCell Collagen® CG, recipient of the Frost & Sullivan Award for Best Collagen Peptide in Personal Care, and is backed by multi-patented Collagen/HA Matrix® Technology, a natural matrix of collagen peptides and hyaluronic acid that is Bio-Optimized™ for maximum effectiveness. The cosmetic-grade technology is combined in CellProof™ Serum with a potent botanical complex and Vitamin C to hydrate, firm, and visibly lift the appearance of dull, dry skin in minutes.

CellProof™ Moisturizer also delivers BioCell Collagen® CG to the skin to hydrate and reduce the appearance of wrinkles. Furthermore, the nourishing formula provides the naturally derived antioxidant astaxanthin, a blend of advanced peptides, Vitamin C, and exotic fruit extracts to support healthy-looking skin and a more even skin tone. Decadent cocoa and shea butter leave skin exceptionally smooth, intensely hydrated, and velvety soft.

CellProof™ Infusion mask, which rounds out the collection, is curated with skin-reviving ingredients such as Ox3™, a proprietary compound that releases oxygen bubbles on contact to waken the skin and make way for two rare botanical extracts, Snow Algae and Summer Snowflake Bulb, to renew the skin. Snow Algae and Summer Snowflake work in tandem to help reduce the appearance of fine lines and wrinkles, giving skin a fresh, vibrant look.

In an ultimate, 360° approach to radiant, youthful-looking skin, Modere has magnified the power of its beauty-boosting, award-winning, patented Collagen/HA Matrix® Technology by pairing the new, topical CellProof™ Essentials Collection with its internally nourishing Liquid BioCell® supplement line. Consumers can choose to complement their skincare regimen with any of Modere’s four Liquid BioCell® supplements, Liquid BioCell® Life, Pure, Skin, or Sport. All four products are scientifically shown to deliver Collagen/HA Matrix® Technology to the skin and connective tissues in an ideal molecular weight that the body can effectively absorb. Their individual formulas differ according to the conditions they are designed to target. Liquid BioCell® Life mitigates the joint discomfort and visible signs of advancing age; Liquid BioCell® Pure, Life’s sister supplement, meets the need of consumers with dietary restrictions; ingredients in Liquid BioCell® Skin bolster the benefits for lustrous, unlined skin; and Liquid BioCell® Sport contains NSF certified factors like BCAAs, L-carnitine, and Rhodiola and astragalus extracts to support optimal physical and mental performance.

Asma Ishaq, CEO of Modere, was on hand at the company’s North America Fall Summit to announce the launch: “Beauty is an inside job, a job our ingestible super nutraceutical, Liquid BioCell, does exceedingly well. Sometimes, though, we want to boost that inner shine. The Modere Inside-Out Beauty System does just that by pairing Liquid BioCell with the new CellProof Essentials Collection in an exclusive 360° approach.”

About Modere

Modere (http://www.modere.com) offers a category-leading portfolio of live clean lifestyle essentials including beauty and personal care, health and wellness, and household products that are equal parts safe, high-performing and scientifically designed. We believe modern health involves pure nutrition, a clean environment and safe ingredients across all our product categories. Modere brings a holistic, live clean approach to well-being, and our products reflect a commitment to excellence and innovation with tested formulas proven around the globe. The recipient of multiple third-party validations, our line includes products that are EPA Safer Choice-approved, EWG Verified™, NSF Certified and gray-water safe. The company is a proud supporter of Vitamin Angels®.

Contact: Mara Quigley

Steve Allen Media

mara@steveallenmedia.com

661.255.8283

—

Share article on social media or email:

Industry: Healthcare

Avalon Realty Associates Sponsors First GRIN2B Foundation Cocktail Reception Fundraiser

Leave a comment


Avalon Realty Associates logo.

Avalon is proud to support the GRIN2B Foundation and happy to assist in an effort to help individuals and families impacted by GRIN2B.


ROLLING MEADOWS, Ill. (PRWEB)

Avalon Realty Associates – a full service commercial real estate company – has announced it will be one of the sponsors of GRIN2B Foundation’s first cocktail reception fundraiser, Gather for GRIN2B. The event will be held at Found Kitchen and Social House in Evanston on Monday, October 7 from 6 p.m. to 9 p.m.

Proceeds from the benefit will fund research on GRIN2B-Related Neurodevelopmental Disorder, which is caused by variations on the GRIN2B gene.

“Avalon is proud to support the GRIN2B Foundation and happy to assist in an effort to help individuals and families impacted by GRIN2B,” said Carlo Santucci, partner at Avalon Realty Associates.

GRIN2B is a gene on the short arm of the 12th chromosome. It’s part of a family of seven genes that encode proteins to form a receptor that relays chemical messages between neurons in the brain, according to GRIN2B Foundation. Individuals affected by a GRIN2B variation can experience developmental delays, speech delay or lack of speech, and low muscle tone, among other symptoms. Associated conditions can also include seizures, cortical visual impairment, Autism Spectrum Disorders, Attention Deficit Hyperactivity Disorder, and/or intellectual disabilities.

The GRIN2B Foundation is a parent-run organization committed to furthering research on the GRIN2B gene and to providing support for individuals and families affected by variations on the gene.

Some other corporate sponsors of Gather for GRIN2B include Stratosphere Networks, Little Steps Pediatric Therapy, Accounting Concepts, Lubin Austermuehle, P.C., and Rothman Law Group.

To get more information about Gather for GRIN2B and purchase tickets, please visit http://www.grin2b.org/Gather-For-GRIN2B/. Sponsorship information is available at http://grin2b.org/sponsor.

About Avalon Realty Associates

Avalon Realty Associates is a full service commercial real estate company that provides real estate brokerage, property investment, tenant representation and property management. For over 25 years, we’ve built trusting relationships with clients and partners and proudly provide real estate services throughout the country and to our community in the Chicago metro area. For more information, please visit https://avalonreal.com/.

For more information contact:

Carlo Santucci

847-506-1000

carlo@avalonreal.com

Share article on social media or email:

Business: Insurance

A New Article Explains How To Avoid Parking Lot Accidents

Leave a comment


News Image

“Do not consider that if you are in a well=monitored public parking lot, you are safe. Parking lots accidents have become more common, mainly due to distracted driving”, said Russell Rabichev, Marketing Director of Internet Marketing Company.


LOS ANGELES (PRWEB)

Although they may look safe, parking lots can be quite hazardous, especially for inexperienced drivers. Official data from the National Safety Council shows that parking lot accidents are more common than one may think. This happens because many drivers are distracted when entering a parking lot. A fifth of car insurance accidents happen in parking lots. To find out more about car insurance, how to avoid accidents and to get free car insurance quotes, visit http://cheapquotesautoinsurance.com/.

For more info and free quotes, visit http://cheapquotesautoinsurance.com/parking-lots-and-car-accidents/

Distracted driving is the main reason why parking lots have become places where accidents happen frequently. A mall parking lot is usually surrounded by huge, flashy billboards. It is easy to lose focus when you are looking on a big screen where the latest offers and discounts are promoted. Keep focus on the road, park the car, then check the ads from a safe place. Also, turn off the smartphone when driving. Some people finding it amusing to take photos of billboards while they enter the parking lot.

Parking lots become crowded during winter holidays. The upcoming Christmas and New Year’s Eve will certainly bring crowds of people to malls and hypermarkets. This means more cars and pedestrians to worry about. With so many blind spots inside a parking lot, the risk of causing an accident is exponentially increased. Pay attention to existing blind spots and slow down. Also consider installing proximity sensors and blind-spot monitors.

Cheapquotesautoinsurance.com is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://cheapquotesautoinsurance.com/.

Share article on social media or email:

Business: Executives

OCT Clinical Trials Appoints Maxime Stevens as Chief Strategy and Development Officer; Poises for Global Expansion

Leave a comment


Maxime Stevens

OCT Clinical Trials announced that it has appointed Maxime Stevens as Chief Strategy and Development Officer.

“I look forward to supporting both strategic onward growth and success of the company, and inspiring our people to learn even more, and become even more.” — Maxime Stevens, Chief Strategy and Development Officer, OCT Clinical Trials


SAINT PETERSBURG, Russia (PRWEB)

OCT Clinical Trials, a leading CRO with operations in Eastern Europe, today announced that it has appointed Maxime Stevens as Chief Strategy and Development Officer. In her role, she is responsible for establishing business development vision, creating roadmaps for global expansion, driving operational excellence and leading short- and long-term global strategy growth operations for the entire company.

“It is both an honor and pleasure for me to be joining OCT Clinical Trials as their Chief Strategy and Development Officer,” Stevens said. “The people are extremely skilled, experienced and passionate about not only our work, but also each other, our sponsors and our partners.”

Maxime brings more than 25 years’ experience in executive leadership, developing Global BD and Operations groups for both American and European companies, including United States Surgical Corporation, Cyberonics Inc., Pierrel Research International AG and Optimapharm. As CEO for Pierrel Research International AG, Maxime was instrumental in wholly restructuring a troubled global company with 28 offices, increasing investments, backlog and revenue pipelines by more than 200%, and securing SIX Swiss Exchange listing of the merged companies in 2014.

Maxime possesses a strong track record of driving long-term growth, operational excellence and expansion of new geographic and channel opportunities for prominent players in the industry. Her extensive international experience, most notably in MENA, Africa, Europe and the United States, is a valuable asset for OCT Clinical Trials as the company moves toward global expansion.

Maxime is also known for her seven-year period running operations for South Africa’s branch of the World Health Organization (WHO). Maxime was recognized by WHO for Outstanding Contribution to Ethics in Business and Humanity, and was an Honored Member of International WHO’s WHO of Professionals in both 2013 and 2014. She also sat for four years on the FDA advisory and ethical boards for Innovative Medical Device approvals.

“I look forward to supporting both strategic onward growth and success of the company, and inspiring our people to learn even more, and become even more. Our best work happens when we embrace making a difference — and then we achieve it,” Maxime added.

Having already gained a sizable market share of trials in Eastern Europe and CIS region, OCT is now taking the significant step of expanding its presence into EMEA, Israel, South Africa, Europe and the United States. With this strategic reinforcement, they will continue to provide the tailor-made solutions they are already known for, now to a broader pool of pharma, biotech and medical device companies.

“We’re a full-service CRO with over 300 projects in our portfolio, solid technological infrastructure and well-run processes with all the main sites within the Eastern European and CIS region,” said Dmitry Sharov, OCT Group President. “We realize that our services and approach are in high demand, not only for sponsors within the region, but for companies worldwide. Maxime Stevens has the proven experience and expertise to strategically develop and drive our expertise into the global arena, and amplify the image of a CRO with an impeccable reputation.”

About OCT Clinical Trials

OCT Clinical Trials is the leading CRO in Russia, with operations in Central and Eastern Europe and the CIS region. With a team of over 200 professionals, the company provides a full range of high-quality clinical research services for phase I-IV and BE studies. With strong local expertise and focus on quality, OCT ensures seamless clinical trial conduct and drug registration on time and within budget. OCT’s experienced team delivers both standalone services such as medical writing, consultancy, project management/monitoring, data management/biostatistics and turnkey service for clinical development. Since 2005, OCT Clinical Trials has worked on over 300 full-service and functional service projects in more than 20 therapeutic areas. Learn more at http://www.OCT-ClinicalTrials.com.

Share article on social media or email:

Health

Mattax Neu Prater Eye Center Now Offering First Trifocal Lens for Cataract Patients

Leave a comment


Jacob Thomas, MD, of Mattax Neu Prater Eye Center

Jacob Thomas, MD, of Mattax Neu Prater Eye Center

It’s truly one-of-a-kind and may be very helpful for those whose lifestyle requires more complete vision.


SPRINGFIELD, Mo. (PRWEB)

Mattax Neu Prater Eye Center now offers its cataract patients the AcrySof® IQ PanOptix® Trifocal Lens, the first and only trifocal intraocular replacement lens (IOL) available in the United States. Implanted during cataract surgery, the PanOptix lens is designed to provide a full range of vision with less dependence on glasses and contacts. This full range includes clear vision at near (e.g. looking at a cell phone), intermediate (e.g. looking at a computer screen), and far (e.g. watching television) distances.

“Cataract correction technology is constantly evolving, so our team is always monitoring these advancements,” says eye surgeon Dr. Jacob Thomas of Mattax Neu Prater. “When we select a new device for our patients, it’s because we believe it’s the most beneficial option for them, not simply because it’s the newest. That is why we are so excited to introduce our cataract patients to the PanOptix trifocal lens. It’s truly one-of-a-kind and may be very helpful for those whose lifestyle requires more complete vision.”

Those interested in learning more about the advanced technology PanOptix IOL should request a cataract consultation by calling Mattax Neu Prater Eye Center at (417) 886-3937 or visiting MattaxNeuPrater.com.

ABOUT MATTAX NEU PRATER EYE CENTER

With five locations in Springfield, Lebanon, Monett, Mountain Grove, and Branson, as well as an onsite surgery center within the Springfield office, Mattax Neu Prater serves patients across the Ozarks. Together, they provide surgical, medical, and primary vision care, including:


  • LASIK laser vision correction

  • Laser-assisted cataract correction with advanced replacement lenses

  • Treatment for glaucoma, diabetic retinopathy, macular degeneration, cornea conditions, and dry eyes

  • Comprehensive eye exams, optical services, and contact lenses

To learn more or request an appointment at Mattax Neu Prater Eye Center, call (417) 886-3937 or visit MattaxNeuPrater.com.

Share article on social media or email:

Science: Biology

Improved Pharma at AAPS with Rapid Fire Presentation, Poster, and Booth

Leave a comment


Improved Pharma at AAPS with Rapid Fire Presentation

A lot of things have changed since we started SSCI, and we still believe in face-to-face interactions with other scientists to discuss research problems and solutions. Now with our new company, Improved Pharma, we are renting a 10 by 10 booth near the posters and will start the process again


WEST LAFAYETTE, Ind. (PRWEB)

Improved Pharma LLC will be presenting their latest research in the area of high-level X-ray methods using synchrotron-produced X-rays to study amorphous drug formulations. On Monday, November 4th, Dr. Pamela Smith, COO of Improved Pharma, will present “Synchrotron X-Ray Diffraction and Pair Distribution Function Analysis of Drug/Polymer Dispersions: A Comparison of Subtraction Techniques to Isolate Intra- and Intermolecular Interactions”. The poster will be presented from 11:30 AM to 12:30 PM in Poster Forum 6. The full abstract of the poster can be accessed here.

On Tuesday, November 5th, Dr. Smith will present “Synchrotron X-ray Analysis of Amorphous Drugs and Drug:Polymer Dispersions” in the Rapid Fire: Formulation and Quality – Chemical session. The session takes place in Exhibit Hall 234 from 3:00 PM to 5:00 PM. Much of our research focuses on using synchrotron X-ray Pair Distribution Function (SXPDF) techniques to probe atom-atom distances in amorphous materials and dispersions. Not all amorphous materials are equivalent, and the PDF patterns reflect the degree of disorder in the materials. SXPDF can provide important regulatory information regarding the sameness of various formulations or lots prepared using different techniques (e.g. spray drying and melt extrusion). SXPDF can also detect neighboring drug molecules in a drug-polymer dispersion. If present, the dispersion is more likely to crystallize as compared to dispersions where no drug domains are detected. This information is extremely important, especially when assessing the risk of a formulation undergoing unwanted changes during manufacturing, scale-up, or storage. SXPDF can also help guide improved formulations of existing products, extending intellectual property protections.

Improved Pharma will be exhibiting in booth 551, conveniently located in the Formulation and Quality section next to Poster Forum 2. We look forward to meeting with you to discuss the latest advances in pharmaceutical research and development. Have a problem with solubility or bioavailability? Want to reformulate your drug product? Looking for assistance with patent litigation? Or, do you just need some analytical testing services? Feel free to stop by to see if we can help you. If you’d like to book an appointment or have a discussion prior to the meeting, please contact us at info@improvedpharma.com.

Stephen Byrn, CSO of Improved Pharma, has a long history associated with the AAPS meeting and was featured as the Member Spotlight of the August 2019 issue of AAPS News Magazine. You can read the article here. As noted in the article, Byrn successfully launched his first business (SSCI) through AAPS. He stated: “My wife and I started our company with only two people. We purchased the AAPS mailing list and taught short courses, both on our own and through AAPS. After we opened our lab, we rented a 10-foot by 10-foot booth near the posters, and I stood in the walkway and told people why they needed our services since we were a research and information company. We eventually grew to 100 employees and sold the company in 2006. Some of the funds from the sale helped fund our work in Africa, especially in the early days. Now we’ve started a new research and information company called Improved Pharma. Although a lot of things have changed since we started our first company, we are still going to rent a 10-foot by 10-foot booth near the posters at this year’s AAPS meeting and start the process all over again.”

About Improved Pharma

Improved Pharma is a research and information company dedicated to improving pharmaceutical methods, formulations, and processes. Dr. Stephen Byrn and Sarah Byrn founded the company in 2006 after the successful acquisition of their first company, SSCI. Dr. Pamela Smith joined the company in 2018 after an 18-year tenure with SSCI. Improved Pharma offers services such as analytical testing, synchrotron-based formulation design, and expert consulting aiding the development and defense of intellectual property matters.

For more information about the techniques discussed in this press release or about Improved Pharma’s services, please contact us at 1-765-463-9951 or info@improvedpharma.com.

Share article on social media or email:

Technology: Electronics

Rigaku presents its X-ray analytical instrumentation at ESSDERC / ESSCIRC 2019

Leave a comment


Rigaku TXRF-V310 for ultra-trace measurement of elemental surface contamination

Rigaku TXRF-V310 semiconductor metrology tool for ultra-trace analysis of elemental surface contamination

Rigaku, a leading supplier of X-ray metrology tools, is the sole Diamond sponsor of the event and is a pioneer and world leader in designing and manufacturing X-ray based measurement tools to solve semiconductor manufacturing challenges.


KRAKOW, Poland (PRWEB)

Rigaku Corporation, a global leader in X-ray analytical technology, is pleased to announce its attendance at the joint meeting of the 49th European Solid State Device Research Conference (ESSDERC) and 45th European Solid State Circuits Research Conference (ESSCIRC). ESSDERC/ESSCIRC is taking place Monday, September 23, through Thursday, September 26, 2019 at the Jagiellonian University Auditorium Maximumin in Kraków, Poland.

The conferences provide an annual European forum for the presentation and discussion of recent advances in solid-state devices and circuits. The increasing level of integration for system-on-chip design made available by advances in semiconductor technology requires a deeper interaction among technologists, device experts, and designers of integrated circuits and systems. While keeping separate Technical Program Committees, ESSDERC and ESSCIRC are governed by a common Steering Committee and share Plenary Keynote Presentations and Joint Sessions bridging both communities.

Rigaku, a leading supplier of X-ray metrology tools, is the sole Diamond sponsor of the event and is a pioneer and world leader in designing and manufacturing X-ray based measurement tools to solve semiconductor manufacturing challenges.

With over 35 years of global market leadership in the semiconductor industry, Rigaku solutions employ X-ray fluorescence (XRF), diffraction (XRD), and reflectometry (XRR) techniques and enable everything from in-fab process control metrology to R&D for thin film and materials characterization, as well as total-reflection XRF spectrometers (TXRF) with integrated vapor phase decomposition (VPD) for trace contamination monitoring.

Systems of note from Rigaku include the Rigaku TXRF-V310 semiconductor metrology system for ultra-trace analysis of elemental surface contamination. The tool employs TXRF analysis for measuring contamination in all fab processes, including cleaning, litho, etch, ashing, and films, It can measure elements from sodium (Na) through uranium (U) with a single-target, 3-beam X-ray system and a liquid nitrogen-free detector system.

The Rigaku MFM310 system is designed for high-volume manufacturing and performs high-precision measurements not possible by optical or ultrasonic techniques. A sophisticated X-ray metrology tool, it enables performance of high-throughput measurements on product and blanket wafers, ranging from ultrathin single-layer films to multilayer stacks.

Also featured is the next-generation Rigaku SmartLab intelligent multipurpose X-ray diffractometer with SAXS and in-plane capabilities. It features the brand new PhotonMax high-flux 9 kW rotating anode X-ray source coupled with a Rigaku HyPix-3000 high-energy-resolution 2D multidimensional semiconductor detector that supports 0D, 1D and 2D measurement modes. The system incorporates a high-resolution θ/θ closed loop goniometer drive system with an available in-plane diffraction arm.

More information about X-ray based measurement tools from Rigaku for semiconductor manufacturing is available at http://www.rigaku.com/products/isemi.

About Rigaku

Since its inception in Japan in 1951, Rigaku has been at the forefront of analytical and industrial instrumentation technology. Rigaku and its subsidiaries form a global group focused on general-purpose analytical instrumentation and the life sciences. With hundreds of major innovations to their credit, Rigaku companies are world leaders in X-ray spectrometry, diffraction, and optics, as well as small molecule and protein crystallography and semiconductor metrology. Today, Rigaku employs over 1,400 people in the manufacturing and support of its analytical equipment, which is used in more than 70 countries around the world supporting research, development, and quality assurance activities. Throughout the world, Rigaku continuously promotes partnerships, dialog, and innovation within the global scientific and industrial communities.

For further information, contact:

Michael Nelson

Rigaku Global Marketing Group

tel: +1. 512-225-1796

michael.nelson@rigaku.com

Share article on social media or email:

health and fitness

Smile Design Studios Named 2019 Top Patient Rated Missouri City Dentist by Find Local Doctors

Leave a comment


News Image

We are so pleased to be recognized as a Top Patient Rated Dentist. We strive to provide an elevated dental experience where both the health and comfort of patients are priorities. Our team offers superior care, using the best that modern dentistry has to offer, says Dr. Simone Ellis.


MISSOURI CITY, Texas (PRWEB)

Find Local Doctors recently honored Smile Design Studios as a 2019 Top Patient Rated Missouri City Dentist. This designation is based on superior ratings and reviews from actual patients. Find Local Doctors is a trusted online directory that helps consumers easily locate qualified and reputable physicians and dentists in their area. Smile Design Studios is among a premier group of dental practices receiving a large number of five-star, positive patient reviews from reputable online sources.

Smile Design Studios, Family and Cosmetic Dentistry, is located at 6130 Highway 6, Missouri City, TX. Dr. Simone Ellis’s modern, state-of-the-art dental practice is equipped to address all aspects of your oral health at every stage of life. Smile Design Studio’s menu of dental services includes ways to protect and restore your teeth. This is as well as offering advanced, cutting-edge treatments to help patients attain healthy, balanced and beautiful smiles. Smile Design Studios is a professional dental practice offering cosmetic dentistry, restorative dentistry and general dentistry services such as teeth whitening, veneers, Invisalign and so much more.

When it comes to your smile, Smile Design Studios stops at nothing less than excellence. Patient reviews mention the friendly, thorough and prompt service provided by Dr. Ellis and her team. The warm, welcoming environment and expert dental care help patients feel at home and make this practice stand out from the rest.

“We are so pleased to be recognized as a Top Patient Rated Dentist. We strive to provide an elevated dental experience where both the health and comfort of patients are priorities. Our team offers superior care, using the best that modern dentistry has to offer,” says Dr. Simone Ellis.

Dr. Simone Ellis earned her Doctor of Dental Medicine degree from Rutgers University School of Dentistry. She is the founder and president of the Houston Minority Dental Society and is an active member of the American Dental Association (ADA), National Dental Association (NDA), American Academy of Implant Dentistry (AAID) and the Greater Houston Dental Society (GHDS). Additionally, Simone is a certified clinical evaluator for The Clinician’s Report and a candidate for Diplomat with the American Academy of Implant Dentistry.

For more information about Smile Design Studios in Missouri City, TX, or to schedule an appointment, please visit http://www.sdshouston.com or call (281)-969-7388.

Share article on social media or email: